BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
- Conditions
- Crohn's Disease
- Interventions
- Drug: PlaceboDrug: BMS-936557 (Anti-IP-10 Antibody)
- First Posted Date
- 2011-11-08
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 121
- Registration Number
- NCT01466374
- Locations
- 🇺🇸
Gastroenterology Research Of New Orleans, Hammond, Louisiana, United States
🇺🇸Southern California Medical Gastroenterology Group, Santa Monica, California, United States
🇺🇸University Of North Carolina At Chapel Hill, Chapel Hill, North Carolina, United States
Korean Post-marketing Surveillance for Sprycel®
- Conditions
- Leukemia, Myelomonocytic, ChronicLeukemia-Lymphoma
- First Posted Date
- 2011-11-03
- Last Posted Date
- 2016-04-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 670
- Registration Number
- NCT01464047
- Locations
- 🇰🇷
Local Institution, Seoul, Korea, Republic of
Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia
- First Posted Date
- 2011-10-26
- Last Posted Date
- 2021-12-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 106
- Registration Number
- NCT01460160
- Locations
- 🇺🇸
University Of Arkansas For Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Miller Children's and Women Hospital, Long Beach, California, United States
🇺🇸Mountain States Tumor Institute, Boise, Idaho, United States
Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications
- Conditions
- Chronic Hepatitis C
- Interventions
- First Posted Date
- 2011-10-19
- Last Posted Date
- 2017-04-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 320
- Registration Number
- NCT01455090
- Locations
- 🇵🇷
Fundacion De Investigacion De Diego, San Juan, Puerto Rico
🇺🇸James J Peters Vamc, The Bronx, New York, United States
🇺🇸Inova Fairfax Hospital, Falls Church, Virginia, United States
Phase 1 Biomarker Study of Anti-PDL-1 in Advanced Melanoma
- Conditions
- Stage III or IV Melanoma
- Interventions
- Biological: BMS-936559 (Anti-PD-L1)
- First Posted Date
- 2011-10-19
- Last Posted Date
- 2011-12-13
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT01455103
Study to Evaluate the Safety, Pharmacokinetics and Tolerability of BMS-708163
- Conditions
- Alzheimer's Disease
- Interventions
- Drug: BMS-708163 (Gamma-Secretase Inhibitor)Drug: Placebo matching BMS-708163
- First Posted Date
- 2011-10-18
- Last Posted Date
- 2011-11-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 116
- Registration Number
- NCT01454115
Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Biological: NivolumabBiological: Ipilimumab
- First Posted Date
- 2011-10-18
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 472
- Registration Number
- NCT01454102
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇨🇦Local Institution, Toronto, Ontario, Canada
Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy
- Conditions
- Non-Hodgkin's LymphomaHodgkin LymphomaMultiple MyelomaChronic Myelogenous Leukemia
- Interventions
- Biological: BMS-936559 (Anti PD-L1)
- First Posted Date
- 2011-10-14
- Last Posted Date
- 2012-02-23
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT01452334
Korean Post-marketing Surveillance for Reyataz®
- First Posted Date
- 2011-10-12
- Last Posted Date
- 2016-04-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 601
- Registration Number
- NCT01450605
- Locations
- 🇰🇷
Local Institution, Seoul, Korea, Republic of
Comparative Tolerability of Protease Inhibitors
- Conditions
- HIV
- First Posted Date
- 2011-10-12
- Last Posted Date
- 2012-12-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 26000
- Registration Number
- NCT01450618